Hepatitis C Infection As A Systemic Disease Extra Hepaticmanifestation Of Hepatitis C An Issue Of Clinics In Liver Disease

Dr. Younossi is a highly-esteemed expert in Hepatitis C Virus (HCV), and for the first time in Clinics in Liver Disease, he has compiled articles that specifically address the extrahepatic manifestation of HCV. Articles are specifically devoted to the following topics: Hepatitis C: A Systemic Disease; Rheumatologic Manifestations of HCV; Cardiovascular Manifestations on HCV; Metabolic Manifestations of HCV (DM, Dyslipidemia); Renal Manifestations of HCV; Lymphoproliferative Disorders Associated with HCV; Depression and HCV; Neurologic Manifestations of HCV; Non-HCC Malignancies in HCV; Dermatologic Manifestations of HCV; Fatigue and Patient-reported Outcomes in HCV; Economic Burden of HCV; and Endocrine Manifestations of HCV (non-dabetes). The thorough coverage of systemic issues will give clinicians the information they need to effectively manage the HCV patient with other health issues.

The field of HCV has changed perhaps faster than any other field in medicine. The Guest Editors have strived to create an issue that is a state-of-the-art analysis of solutions to specific challenges faced in the United States and globally in implementing HCV elimination strategies. They believe that clinicians now have the tools and road maps needed to accomplish this goal. The clinical review articles in this issue accomplish that: Using Existing Health Care Infrastructure To Expand HCV Care; Creating A Reproducible Health Economic Model To Describe The Burden Of HCV And Cost Of Treatment In Any Country; The Best Uses Of Cost-Effectiveness Models In HCV; Increasing Access To HCV Care In Corrections; Cure As Prevention Strategies For HCV In People Who Inject Drugs; Australia Will Eliminate HCV – How It Works; New York Is The First State In The US To Develop An HCV Elimination Strategy; When HCV Diagnostics Are The Barrier To Care; Key Findings From The Checs HCV Cohort Study; Strategies To Reduce HCV Reinfection Rates In People Who Inject Drugs; Strategies To Reduce HCV Reinfection Rates In Men Who Have Sex With Other Men; The Value Of Curing HCV From A Payer’s Perspective; How To Expand Care Capacity In HCV; Strategies To Eliminate HCV In The HIV Coinfected Population; and The US Veteran’s Administration: Lessons Learned And Best Practices For HCV Elimination.

Dr. Pyrsopoulos has assembled the top authors in the field to provide current reviews on acute liver failure, to be the first time this topic is addressed in one volume. Topics are devoted to Classification and Epidemiologic Aspects of Acute Liver Failure; Acute Liver Failure: Mechanisms of disease and multi-systemic involvement; The Pathology of Acute Liver Failure; Liver Regeneration in the Acute Liver Failure Patient; Viral Hepatitis and Acute Liver Failure: Still a Problem; Drug- induced Liver Injury and Acute Liver Failure; Acetaminophen and Acute Liver Failure; Non-Viral Or Drug-Induced Etiologies of Acute Liver Failure; The Clinical Spectrum and Manifestations of Acute Liver Failure; Non ICU Management of Acute Liver Failure; Management of Acute Liver Failure in the ICU Setting; Prognostic Models of Acute Liver Failure; The Role of Liver Transplantation in Acute Liver Failure; and Future Approaches and Therapeutic Modalities for Acute Liver Failure. Readers will come away with a current point of view about how to approach and manage the patient with acute liver failure.

Consultations of Gastroenterology practitioners are frequently sought for many complex issues relating to acute and chronic liver disease. Many of the disease entities are uncommon and complicated in scope. Liver disease may occur in the setting of other chronic medical conditions and involve other organ systems, with recommendations for diagnostic strategies and therapeutic approaches somewhat challenging. Serious consequences are often the rule with misdiagnosed or inadequately treated liver disease. Dr. Flamm has provided a framework for approaching consultation for common liver-related problems for the gastroenterology practitioner. Articles are devoted to the following topics: Common Findings and Interpretation for the Clinician; Genetic Testing in Liver Disease: What to Order and When; Acute Liver Failure; Liver Disease in Oncology Patients; Primary Sclerosing Cholangitis: What the Gastroenterologist/Hepatologist Needs to Know; An Update on the Treatment and Follow up of Patients with PBC; Wilson’s Disease: Diagnosis, Treatment, and Follow Up; Follow Up of the Post-Liver Transplantation Patient: A Primer for the Practicing Gastroenterologist; Liver Disease in Patients on Total Parenteral Nutrition; Treatment Strategies in NAFLD: What’s Coming; Resistance Testing in Chronic HCV; and HCV genotype 3: Treatment Approach and Natural History.

Obesity has devastating effects on a patient's overall health, with specific negative effects on organ systems, long-term. The hepatologist must often manage diseases of the liver and pancreas as a result of obesity. This issue will provide a current update on the diagnosis, treatment, and management of NAFLD and NASH. Dr. Bernstein has assembled the top leaders in the field to provide timely clinical reviews. Articles are devoted to the following topics: Clinical and economic burden of NAFLD/NASH; NAFLD/NASH in children and its implications; Natural history of NAFLD/NASH; Diagnosis and evaluation of NAFLD/NASH; Radiological imaging in NAFLD/NASH; The use of liver biopsy in NAFLD: When to biopsy and in whom; Pathophysiology of NAFLD/NASH; Risk factors for the development of NAFLD/NASH including genetics; Role of intestinal microbes in NAFLD/NASH; NAFLD/NASH and the metabolic syndrome; NAFLD/NASH and lipid and insulin resistance; NAFLD/NASH and cardiac disease; Current treatment of NAFLD/NASH; Emerging treatment of NAFLD/NASH; NAFLD/NASH and HCC and NAFLD/NASH and liver transplantation. Readers will have a clear understanding of how to manage outcomes for these patients.

Clinical information about Hepatitis C is quickly outdated, so Dr. Poordad has assembled expert authors to provide state-of-the-art clinjcal reviews for hepatologists. This issue is uniquely organized to present articles based on therapeutic regimens for certain types of patients: Regimens for the Treatment-Naïve Patient; Regimens for Treatment of the Interferon-Failure Patient; Regimens for DAA Failure Patients; Regimens for the Cirrhotic Patient; Regimens for the Peri-Transplant Patient; Regimens for the HIV-Co-Infected Patient; and Next-generation Regimens: The Future of HCV Therapy. This presentation will be very clinically relevant for the practicing hepatologist.

Hepatitis C infection can be an acute or chronic illness and is the most common cause of liver disease in the US. It often goes undiagnosed until significant organ damage has occurred. This issue of the ID Clinics discusses the staging of liver disease, treatments for those newly diagnosed, and those who are dealing with chronic illness, along with managing drug therapy and virus resistance.

This book helps scientists, clinicians and other interested individuals understand recent clinical advances and challenges for the future. It covers many basic aspects of the pathogenesis of chronic hepatitis C, HCV infections in particular populations, approaches to therapy, and prevention and control of HCV Infection. The book provides a succinct review of the large amount of data generated by multiple groups over the past two decades that has revealed the natural history of HCV infection. Similarly, it summarizes current understanding of the origins of HCV-associated hepatocellular carcinoma, cirrhosis and hepatic fibrosis. Extra-hepatic manifestation and metabolic disorders related to HCV infection are described. In this volume, these clinically important aspects of HCV infection are comprehensively described. Highlights are description of newly developed direct- acting antivirals. The authors represent a worldwide distribution of leaders in the field reflecting the global nature of HCV infection. Based on recent data concerning the genetic- and geographical diversity of HCV, and increased global disease burden of HCV infection, challenges for global control of HCV infections are described.